바이오모아 (BioMoa) — ADC · Antibody

9268프로그램 35FDA 승인

166오늘 방문

738누적 방문

8122갱신 대기 S–CData Tier S/A/B차세대 1068HER2 breast 5456Antibody 2744CGT →Psoriasis →NSCLC 35FDA 승인

피드 Data Tier 차세대

최근 활동

RSS →

CGTAAVBiologicstaleNeurologix, Inc.Phase 2

Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus (Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus)

Parkinson's Disease · Parkinson's Disease

#ParkinsonsDisease#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 DISCONTINUED

CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

anti-CD19 IL10/IL15 CAR-NK (anti-CD19 IL10/IL15 CAR-NK)

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTBiologicstaleWest China HospitalPhase 1

JWK010 gene therapy (JWK010 gene therapy)

Oculocutaneous Albinism (OCA) · Oculocutaneous Albinism (OCA)

#OculocutaneousAlbinismOCA#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

AntibodystaleJanssenApproved

Infliximab Dose Intensification (Infliximab Dose Intensification)

Crohn Disease (CD) · Crohn Disease (CD)

#CrohnDiseaseCD#Antibody#Approved#항체#면역항체+2

임상시험 1상태 RECRUITING

CGTBiologicstaleGenSight BiologicsPhase 2

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

Non-syndromic Retinitis Pigmentosa · Non-syndromic Retinitis Pigmentosa

#Non-syndromicRetinitisPigmentosa#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTAAVBiologicstaleSpark Therapeutics, Inc.Phase 2

AAV2-hCHM (AAV2-hCHM)

Choroideremia; CHM (Choroideremia) Gene Mutations · Choroideremia

#Choroideremia#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTAAVBiologicstaleMeiraGTx UK II LtdPreclinical

AAV OPTIRPE65 (AAV OPTIRPE65)

Leber Congenital Amaurosis (LCA); Eye Diseases · Leber Congenital Amaurosis (LCA)

#LeberCongenitalAmaurosisLCA#CGT#Preclinical#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTAAVBiologicstaleMeiraGTx UK II LtdPreclinical

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

Achromatopsia · Achromatopsia

#Achromatopsia#CGT#Preclinical#세포유전치료#CAR-T+2

임상시험 1상태 DISCONTINUED

CGTAAVBiologicstaleAspa TherapeuticsPhase 2

AAV9 BBP-812 (AAV9 BBP-812)

Canavan Disease · Canavan Disease

#CanavanDisease#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleWashington Research FoundationPhase 1

FH FOLR1 ST CAR T-cells (FH FOLR1 ST CAR T-cells)

Advanced Osteosarcoma; Recurrent Osteosarcoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

CGTAAVBiologicstaleYAP Therapeutics, Inc.Phase 1

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

Heart Failure With Reduced Ejection Fraction · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

CGTAAVBiologicstaleeyeDNA TherapeuticsPhase 2

AAV2/5-hPDE6B (AAV2/5-hPDE6B)

Retinitis Pigmentosa · Retinitis Pigmentosa

#RetinitisPigmentosa#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 DISCONTINUED

ADCBiologicstaleCancer Institute and Hospital, …Phase 2

TAEST1901 (TAEST1901)

Rare Malignant Neoplasm; Advanced Solid Tumors · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

AntibodystaleJanssenApproved

ustekinumab (Stelara, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab)

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#항체#면역항체+2

임상시험 1상태 RECRUITING

ADCBiologicstaleBeOne MedicinesPhase 1

BG-C0979 (BG-C0979)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleCSPC Megalith Biopharmaceutical…Phase 2

SYH2051 tablets (SYH2051 tablets)

Advanced Solid Tumors; Breast Cancer · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

CGTBiologicstaleLions Eye Institute, Perth, Wes…Phase 2

rAAV.sFlt-1 (rAAV.sFlt-1)

Macular Degeneration; Age-related Maculopathies · Macular Degeneration

#MacularDegeneration#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

ADCBiologicstaleLepu Biopharma Co., Ltd.Phase 2

MRG004A (MRG004A)

Advanced or Metastatic Solid Tumors · Advanced or Metastatic Solid Tumors

#AdvancedorMetastaticSolidTumors#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 ACTIVE

AntibodystaleDan LiangPhase 2

adalimumab (Humira, reduction or discontinuation of Adalimumab)

Uveitis; Adalimumab · Uveitis

#Uveitis#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

AntibodystaleQuantumLeap Healthcare Collabor…Phase 2

trastuzumab (Herceptin, AMG 386 with or without Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

ADCBiologicstaleShanghai Ninth People's Hospita…Phase 2

sacituzumab govitecan (Trodelvy, Becotatug Vedotin or Sacituzumab Tirumotecan)

Adenoid Cystic Carcinoma of the Head and Neck; SBRT · Adenoid Cystic Carcinoma of the Head and

#AdenoidCysticCarcinomaoftheHeada#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

CGTBiologicstaleBeacon TherapeuticsPhase 2

rAAV2-CB-hRPE65 (rAAV2-CB-hRPE65)

Leber Congenital Amaurosis · Leber Congenital Amaurosis

#LeberCongenitalAmaurosis#CGT#Phase2#세포유전치료#CAR-T+2

효능 ORR 2%임상시험 1상태 ACTIVE

ADCBiologicstaleAstraZenecaPhase 2

[11C]AZ1419 3391 ([11C]AZ1419 3391)

Advanced Solid Malignancies · Advanced Solid Malignancies

#AdvancedSolidMalignancies#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleCancer Institute and Hospital, …Phase 2

PRG2505 (PRG2505)

Rare Malignant Neoplasm; Advanced Solid Tumors · Rare Malignant Neoplasm

#RareMalignantNeoplasm#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

AntibodystaleJanssenApproved

ustekinumab (Stelara, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib)

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#항체#면역항체+2

임상시험 1상태 RECRUITING

77 / 167 페이지

← 이전 다음 →

전체 9,268개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 166 / 738

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus (Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus)

anti-CD19 IL10/IL15 CAR-NK (anti-CD19 IL10/IL15 CAR-NK)

JWK010 gene therapy (JWK010 gene therapy)

Infliximab Dose Intensification (Infliximab Dose Intensification)

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

AAV2-hCHM (AAV2-hCHM)

AAV OPTIRPE65 (AAV OPTIRPE65)

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

AAV9 BBP-812 (AAV9 BBP-812)

FH FOLR1 ST CAR T-cells (FH FOLR1 ST CAR T-cells)

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

AAV2/5-hPDE6B (AAV2/5-hPDE6B)

TAEST1901 (TAEST1901)

ustekinumab (Stelara, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab)

BG-C0979 (BG-C0979)

SYH2051 tablets (SYH2051 tablets)

rAAV.sFlt-1 (rAAV.sFlt-1)

MRG004A (MRG004A)

adalimumab (Humira, reduction or discontinuation of Adalimumab)

trastuzumab (Herceptin, AMG 386 with or without Trastuzumab)

sacituzumab govitecan (Trodelvy, Becotatug Vedotin or Sacituzumab Tirumotecan)

rAAV2-CB-hRPE65 (rAAV2-CB-hRPE65)

[11C]AZ1419 3391 ([11C]AZ1419 3391)

PRG2505 (PRG2505)

ustekinumab (Stelara, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus (Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus)

anti-CD19 IL10/IL15 CAR-NK (anti-CD19 IL10/IL15 CAR-NK)

JWK010 gene therapy (JWK010 gene therapy)

Infliximab Dose Intensification (Infliximab Dose Intensification)

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

AAV2-hCHM (AAV2-hCHM)

AAV OPTIRPE65 (AAV OPTIRPE65)

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

AAV9 BBP-812 (AAV9 BBP-812)

FH FOLR1 ST CAR T-cells (FH FOLR1 ST CAR T-cells)

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

AAV2/5-hPDE6B (AAV2/5-hPDE6B)

TAEST1901 (TAEST1901)

ustekinumab (Stelara, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab)

BG-C0979 (BG-C0979)

SYH2051 tablets (SYH2051 tablets)

rAAV.sFlt-1 (rAAV.sFlt-1)

MRG004A (MRG004A)

adalimumab (Humira, reduction or discontinuation of Adalimumab)

trastuzumab (Herceptin, AMG 386 with or without Trastuzumab)

sacituzumab govitecan (Trodelvy, Becotatug Vedotin or Sacituzumab Tirumotecan)

rAAV2-CB-hRPE65 (rAAV2-CB-hRPE65)

[11C]AZ1419 3391 ([11C]AZ1419 3391)

PRG2505 (PRG2505)

ustekinumab (Stelara, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus (Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus)

anti-CD19 IL10/IL15 CAR-NK (anti-CD19 IL10/IL15 CAR-NK)

JWK010 gene therapy (JWK010 gene therapy)

Infliximab Dose Intensification (Infliximab Dose Intensification)

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

AAV2-hCHM (AAV2-hCHM)

AAV OPTIRPE65 (AAV OPTIRPE65)

Prior exposure to AAV-CNGA3 or AAV-CNGB3 (Prior exposure to AAV-CNGA3 or AAV-CNGB3)

AAV9 BBP-812 (AAV9 BBP-812)

FH FOLR1 ST CAR T-cells (FH FOLR1 ST CAR T-cells)

AAV9-Sav-shRNA (YAP101, YAP101 (AAV9-Sav-shRNA))

AAV2/5-hPDE6B (AAV2/5-hPDE6B)

TAEST1901 (TAEST1901)

ustekinumab (Stelara, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab)

BG-C0979 (BG-C0979)

SYH2051 tablets (SYH2051 tablets)